What's in Zynerba Pharmaceuticals, Inc.'s pipeline?

Zynerba Pharmaceuticals, Inc. has 2 drugs in our index: 0 marketed, 0 filed, 1 in Phase 3, 1 in Phase 2, 0 in Phase 1.

Which companies overlap with Zynerba Pharmaceuticals, Inc.'s portfolio?

Top competitors by shared drug class: Aphios, Azienda Ospedaliera Universitaria Policlinico "G. Martino", Scilex Pharmaceuticals, Inc., Wolfson Medical Center.

How do I subscribe to ongoing alerts?

Subscribe to /feed/company/zynerba-pharmaceuticals-inc.xml in any RSS reader. Every regulatory action and pipeline update lands in your feed.

Last reviewed 2026-05-16 · How we verify

Zynerba Pharmaceuticals, Inc. — Portfolio Competitive Intelligence Brief

Zynerba Pharmaceuticals, Inc. pipeline: 0 marketed, 0 filed, 1 Phase 3, 1 Phase 2. Recent regulatory actions, upcoming PDUFA, patent timeline, top competitor overlap.

0 marketed 0 filed 1 Phase 3 1 Phase 2 0 Phase 1 Live · 30-min refresh

Portfolio leaders (marketed + Phase 3 / filed)

Drug	Generic	Phase	Class	Target	Area	First approval
ZYN002 - transdermal gel	ZYN002 - transdermal gel	phase 3	cannabinoid	CB2 receptor	Epilepsy

Therapeutic area mix

Epilepsy · 1

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this portfolio.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this portfolio.

Patent timeline (forward window)

No upcoming patent expiries for this portfolio.

Competitive overlap (companies sharing drug classes)

Aphios · 1 shared drug class
Azienda Ospedaliera Universitaria Policlinico "G. Martino" · 1 shared drug class
Scilex Pharmaceuticals, Inc. · 1 shared drug class
Wolfson Medical Center · 1 shared drug class

Subscribe to ongoing alerts

Every new pipeline event for Zynerba Pharmaceuticals, Inc.:

Cite this brief

Drug Landscape (2026). Zynerba Pharmaceuticals, Inc. — Portfolio Competitive Intelligence Brief. https://druglandscape.com/ci/company/zynerba-pharmaceuticals-inc. Accessed 2026-05-16.